South Korea's STgen Bio, a biopharmaceutical contract development and manufacturing organisation (CDMO) under Dong-A Socio Holdings, has announced an investment of 110 billion won ($73.8 million/€68.1m) to expand its manufacturing facilities in Incheon. Korea JoongAng Daily reported on the announcement on 13 March 2026.

The investment will be allocated toward expanding drug substance and drug product facilities, with construction scheduled to begin in the first quarter of 2026 and completion targeted for the first quarter of 2028.

Upon completion, STgen Bio's total annual production capacity will reach 14,000 litres (3,700 gallons). Drug substance capacity is expected to increase by approximately 44%, while drug product capacity will increase by 170%.

The expansion includes the addition of two new bioreactors, an advanced harvesting system, and a state-of-the-art isolator-based drug product filling line.

The new mid-scale manufacturing lines are designed for the production of multiple biopharmaceutical products, enabling STgen Bio to support global pharmaceutical partners across various stages of development and commercial manufacturing.

An STgen Bio source said: "Leveraging our global regulatory track record and commercial manufacturing expertise, we continue to strengthen our position in the high-value biologics manufacturing sector. This expansion will allow us to broaden our global client base and further diversify our customer and revenue portfolio across international markets, reinforcing our position as a global contract development and manufacturing organisation."

Founded in September 2011 under the name DM Bio, STgen Bio is a biopharmaceutical company operating under Dong-A Socio Holdings.

Access the full report on STgen Bio's manufacturing expansion here.